Ahren 2004

1 Treatments

**Studied treatment**  
vildagliptin 50 mg daily (add-on to metformin therapy)

**Control treatment**  
placebo (add-on to metformin therapy)

**Concomittant treatments**  
-

2 Patients

**Patients**  
patients with type 2 diabetes

**Inclusion criteria**  
-

**Exclusion criteria**  
-

3 Methods

**Blinding**  
double-blind

**Design**  
-

**Centers**  
-

**Geographical area**  
-

**Sizes**  
56/51

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>stroke</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>HbA1c goal &lt;7 all cause deaths</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>nephropathy</td>
<td>-/56</td>
<td>-/51</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV events</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV deaths</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>MI</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all hypoglycemia</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Adverse events leading to treatment discontinuation</td>
<td>0/56</td>
<td>0/51</td>
<td>0.91</td>
<td>[0.02; 46.76]</td>
</tr>
</tbody>
</table>
5 References